No data to show
XHKG
2096
Market cap3.88bUSD
Aug 08, Last price
12.31HKD
1D
-1.36%
1Q
38.63%
IPO
11.91%
Name
Simcere Pharmaceutical Group Ltd
Chart & Performance
P/E
38.03
P/S
4.20
EPS
0.30
Div Yield, %
1.43%
Shrs. gr., 5y
-0.67%
Rev. gr., 5y
5.67%
Revenues
6.64b
+0.41%
Net income
733m
+2.57%
CFO
0k
-100.00%
Dividend
Jun 18, 20250.17129 HKD/sh
Earnings
Aug 19, 2025
Profile
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 6,635,211 0.41% | 6,607,805 4.57% | 6,319,096 26.39% | |||||
Cost of revenue | 5,757,853 | 6,031,005 | 5,897,087 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 877,358 | 576,800 | 422,009 | |||||
NOPBT Margin | 13.22% | 8.73% | 6.68% | |||||
Operating Taxes | 86,713 | 26,088 | (40,478) | |||||
Tax Rate | 9.88% | 4.52% | ||||||
NOPAT | 790,645 | 550,712 | 462,487 | |||||
Net income | 733,165 2.57% | 714,761 -23.22% | 930,868 -38.23% | |||||
Dividends | (419,218) | (391,296) | ||||||
Dividend yield | 2.39% | 1.29% | ||||||
Proceeds from repurchase of equity | (289,073) | |||||||
BB yield | 1.65% | |||||||
| Debt | ||||||||
Debt current | 1,118,698 | 1,094,981 | 1,350,823 | |||||
Long-term debt | 240,647 | 542,488 | 370,598 | |||||
Deferred revenue | 403,350 | |||||||
Other long-term liabilities | 1,624,162 | 610,788 | ||||||
Net debt | (2,476,567) | (1,960,672) | (3,456,269) | |||||
| Cash flow | ||||||||
Cash from operating activities | 151,048 | 1,354,712 | ||||||
CAPEX | (483,182) | (678,005) | ||||||
Cash from investing activities | 1,087,807 | 68,306 | ||||||
Cash from financing activities | (894,834) | (753,681) | ||||||
FCF | 977,342 | (495,748) | 338,362 | |||||
| Balance | ||||||||
Cash | 1,943,069 | 2,018,299 | 2,621,826 | |||||
Long term investments | 1,892,843 | 1,579,842 | 2,555,864 | |||||
Excess cash | 3,504,151 | 3,267,751 | 4,861,735 | |||||
Stockholders' equity | 7,068,115 | 7,222,736 | 6,368,435 | |||||
Invested Capital | 6,397,495 | 5,994,997 | 4,046,761 | |||||
ROIC | 12.76% | 10.97% | 10.17% | |||||
ROCE | 8.86% | 6.23% | 4.68% | |||||
| EV | ||||||||
Common stock shares outstanding | 2,519,978 | 2,608,534 | 2,620,376 | |||||
Price | 7.10 5.50% | 6.73 -42.08% | 11.62 33.26% | |||||
Market cap | 17,891,847 1.92% | 17,555,433 -42.34% | 30,448,768 33.72% | |||||
EV | 15,415,280 | 15,594,761 | 27,008,561 | |||||
EBITDA | 877,358 | 886,394 | 704,937 | |||||
EV/EBITDA | 17.57 | 17.59 | 38.31 | |||||
Interest | 34,568 | 34,408 | ||||||
Interest/NOPBT | 5.99% | 8.15% | ||||||